Curriculum vitae
CV
Research and experience in pharmacometrics and clinical pharmacology.
Profile
| Name | Zack (Zehua) Wang |
| Role | PhD candidate in Pharmacology, University of Auckland |
| Focus | Pharmacometrics, clinical trial simulation and model-informed dosing |
| Contact | zack.wang@auckland.ac.nz · LinkedIn |
| Location | Auckland, New Zealand |
Education
-
Dec 2025–present Doctor of Philosophy in Pharmacology
University of Auckland - Thesis: Advancing the Evidence for Model-Based Dosing in the Clinical Setting.
- Supervisors: Jacqueline Hannam, Jeff Harrison and Hesham Al-Sallami.
-
Sep 2022–Jun 2025 Master of Science in Pharmacokinetics
China Pharmaceutical University, Nanjing, China -
Sep 2018–Jun 2022 Bachelor of Engineering in Pharmaceutical Engineering
Shandong First Medical University, Jinan, China
Research
-
Dec 2025–present Clinical trial simulation for model-based dosing
University of Auckland - Developing a reusable clinical trial simulation framework to compare dosing and sampling strategies, starting with data-rich vancomycin cohorts and accounting for treatment delivery.
-
2025–present Antibody therapies in Alzheimer's disease
University of Auckland - Investigating variation in response and the persistence of donanemab benefit after treatment cessation in early Alzheimer's disease.
- Reproduced four benchmark models in NONMEM using simulated data, with predictive checks and bootstrap sensitivity analyses. Supported by the HOPE Foundation for Research on Ageing.
- Supervisors: Jacqueline Hannam and Nick Holford.
-
Mar 2023–Jul 2025 PBPK–PD modelling of antibody–drug conjugates
China Pharmaceutical University - Developed a translational PBPK–PD model of antibody–drug conjugates, linking drug and payload disposition to tumour response in mice and humans.
- Simulations predicted greater interstitial lung disease risk with increasing age and dose for trastuzumab deruxtecan.
-
Sep 2022–Jun 2025 Transporter-mediated drug disposition
China Pharmaceutical University - Contributed to model evaluation and pharmacokinetic investigation in cross-species PBPK modelling of SPT-07A, accounting for hepatic and extrahepatic glucuronidation in rats, dogs and humans.
- Investigated blood–brain barrier transport in rats with chronic liver injury through experimental work and data analysis. Reduced cerebral carnitine and acetylcarnitine were linked partly to OCT1/2 and OCTN2 downregulation.
- Examined renal drug transport in rats with acute liver injury through experimental work and data analysis, linking reduced OCT2/MATE1 expression and function to impaired metformin excretion and increased plasma exposure.
Academic Experience
-
Aug 2026–present Academic Casual
University of Auckland, Faculty of Medical and Health Sciences -
Dec 2025–Jul 2026 Professional Casual
University of Auckland, Department of Pharmacology and Clinical Pharmacology - Developed and tested an R Shiny Ames Test virtual laboratory for MEDSCI 318, with interactive dose–response scenarios, validation checks, data export and a student guide.
Selected Publications
- Wang Z et al. PBPK-PD model for predicting pharmacokinetics, tumor growth inhibition, and toxicity risks of topoisomerase inhibitor ADCs in mice and humans. European Journal of Pharmaceutical Sciences, 2025.
- Zhu X et al. Prediction of SPT-07A Pharmacokinetics in Rats, Dogs, and Humans Using a Physiologically-Based Pharmacokinetic Model and In Vitro Data. Pharmaceutics, 2024.
- Zhi H et al. Chronic liver injury decreases levels of cerebral carnitine and acetylcarnitine in rats partly due to the downregulation of organic cation transporters OCT1/2 and OCTN2 at the blood-brain barrier. Drug Metabolism and Disposition, 2025.
- Zhi H et al. Thioacetamide-Induced Acute Liver Injury Increases Metformin Plasma Exposure by Downregulating Renal OCT2 and MATE1 Expression and Function. Biomedicines, 2023.
Selected Presentations
-
2026 - Presented vancomycin clinical trial simulation at PAGANZ, Melbourne (poster and lightning talk); WCP2026, Melbourne (poster); and ASCEPT New Zealand, Christchurch (oral presentation).
- Presented at Te AO and HealtheX. Alzheimer's disease research abstract published for the HOPE Knowledge Exchange.
-
2024 - PBPK–PD modelling of antibody–drug conjugates, 14th Academic Conference on Drug and Chemical Foreign Metabolism, Nanjing; awarded poster presentation.
Academic Service
-
Professional societies
- Student Representative, Population Approach Group of Australia and New Zealand (PAGANZ), 2026–present.
- Committee Member, ISoP Student, Trainee, Early-Career Professional (STEP) Committee, 2026–present.
- Committee Member, ASCEPT Aotearoa New Zealand Forum, 2026–present.
- Member, New Zealand Association of Gerontology, since August 2026.
-
University of Auckland
- Co-Lead, Judging and Prizes Committee, HealtheX 2026.
- PGSA Education Representative, FMHS Education Committee.
- Postgraduate Representative, Biomedical Science Board of Graduate Studies.
Selected Awards
-
2026 - HOPE Foundation for Research on Ageing Scholarship.
- ASCEPT Student Travel Grant for WCP2026.
- PAGANZ Student Travel Award.
-
2025 - Outstanding Graduate, China Pharmaceutical University.
-
2024 - Exploring the World Scholarship, China Pharmaceutical University.
- Awarded Poster Presentation, Chinese Pharmacological Society.
-
2022–2025 - Academic Scholarship, China Pharmaceutical University, for three consecutive academic years.
-
2022 - Outstanding Graduate, Shandong First Medical University.
-
2019–2021 - Academic Scholarships, Shandong First Medical University, for two consecutive academic years.
Skills
-
Modelling and computing
- Population PK/PD, disease progression modelling, clinical trial simulation and PBPK/PD.
- R, Python, MATLAB, NONMEM, Wings for NONMEM, Monolix, PK-Sim and Phoenix WinNonlin.
- Reproducible analysis, scientific visualisation and interactive teaching tools.
-
Experimental methods and communication
- Animal and cell studies; Western blot, PCR, ELISA, HPLC-MS and imaging.
- Scientific writing, posters and oral presentations; photography and short-film production.